Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AMAG Pharmaceutocals Reveal Positive Results From Phase III Study Of Feraheme

RELATED NEWS
Trade AMAG now with 

AMAG Pharmaceuticals Inc (AMAG: Quote) Wednesday announced positive preliminary results from the second phase III study for Feraheme in patients with iron deficiency anemia or IDA, regardless of the underlying cause.

The biopharmaceutical company stated that the study, called as IDA-301, compared Feraheme treatment to placebo and enrolled patients having IDA associated with various conditions including abnormal uterine bleeding, cancer, gastrointestinal disorders or other causes.

The company further stated that Feraheme demonstrated superiority on all primary efficacy endpoints evaluated in this study.

The company added that the efficacy and safety of Feraheme in this study were comparable to that reported in the IDA-302 study, the phase III IDA study comparing Feraheme to iron sucrose.

In the IDA-301 study, Feraheme demonstrated robust efficacy, achieving superiority on both primary efficacy endpoints. Patients treated with Feraheme achieved a statistically significant mean increase in hemoglobin at week five of 2.7 g/dL, compared to a mean increase of only 0.1 g/dL in patients who received placebo; importantly, these data are consistent with the 2.7 g/dL increase in hemoglobin reported in the IDA-302 study,

Register
To receive FREE breaking news email alerts for AMAG Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
There are just two days to go for the big event of India making its maiden foray to Mars. The nation's first interplanetary probe known as Mars Orbiter Mission (MOM) spacecraft is scheduled to enter the Martian orbit at 7.30 AM IST on September 24, 2014. A US satellite to study Mars' upper atmosphere has entered the Red Planet's orbit. NASA said its Mars Atmosphere and Volatile Evolution (MAVEN) spacecraft successfully entered the orbit at 10:24 p.m. EDT Sunday, completing a 10-month interplanetary journey of 442 million miles, or 711 million kilometers. MAVEN is the first spacecraft dedicated to exploring the tenuous higher atmosphere of Mars. Bundesbank President Jens Weidmann has criticized the European Central Bank's latest measures to boost the euro area economy, such as the planned purchases of covered bonds and asset-backed securities and covered bonds, as well as the interest rate reduction this month. The latest decisions suggest...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.